Introduction
Hypothyroidism is a common endocrine disorder resulting commonly from failure of the gland to produce adequate amounts of hormone. Primary gland failure accounts for 90% to 95% of all hypothyroid cases. Many of these patients show evidence of an autoimmune origin of thyroid failure, with > 95% developing antithyroid peroxidase antibody and/or antithyroglobulin (anti-Tg) antibodies. The TSH level is usually very high (>15.0miu/L) with depression of FT4 (<1.0ng/dl). 1, 2 The prevalence rate of hypothyroidism depends upon population studied. Prevalence of primary hypothyroidism is 1:100 but may increase to 5:100 if patients with sub-clinical hypothyroidism are included. 3 In the Framingham study, the prevalence rate of hypothyroidism was up to 20%. 4, 5 In all studies, it was shown that a progressive increase in prevalence of thyroid antibodies was revealed with age in women, as compared to in men. These trends were confirmed in the original Whickham survey but the frequency of positive tests was lower. 7 Most patients with spontaneous hypothyroidism have underlying chronic lymphocytic (autoimmune) thyroiditis and positive results on thyroid-antibody testing. In a review of three longitudinal studies (with 6, 10 and 20 years follow-up) of 2956 subjects, mild thyroid failure occurred at a rate of 2.1% to 3.8% per year in thyroid-antibody positive patients and in 0.3% per year in thyroid-antibody negative patients. 9 The development of hypothyroidism also correlated with the strength of titre of antithyroid microsomal antibody at first survey. 10 There is a definite relationship between Lthyroxine therapy and fall of thyroid microsomal and thyroglobulin antibodies in idiopathic myxoedema and in hypothyroid but not in euthyroid Hashimoto's thyroiditis. Chiovato Let al 14 studied in this context. The changes in the serum thyroid auto-antibodies, anti-thyroglobulin (TgAb) and anti-thyroid-peroxidase (TPO-Ab), Lipid profile and thyroid volume following Lthyroxine therapy is still a controversial matter. Romaldini JH et al 15 studied 23 patients with goiter due to Hashimoto's thyroiditis, 10 had clinical hypothyroidism (CH) and 13 had subclinical hypothyroidism (SH). Both groups received L-T4 (2.0-2.5 micro.gm/kg/d) for a median of 6 months. Serum concentration of TgAb (normal value <200 IU/mL) and TPO-Ab (normal value <150 IU/mL) were measured by a sensitive IRMA using 1251 protein-A. At the end of observation period the median serum TSH concentration decreased significantly in both groups (42.9 to 0.55 in CH and 2.4 to 0.74 mIU/L in SH patients) and serum FT4 levels increased only in the CH group (0.87 to 2.1, P < 0.05). TPOAb levels fall in the CH groups (871 to 194 IU/mL, P < 0.05) and no significant change was noted in SH patients (260 to 116 IU/mL).
Materials and Methods
The study was carried out in the Department of It was a Hospital based prospective study for estimation of thyroid peroxidase antibody among the hypothyroid patients and to find out the clinical and biochemical response of L-thyroxine therapy in the hypothyroid patients with positive thyroid peroxidase antibody. The clinical course of the disease was explained with each patient in details and they were enrolled after obtaining informed written consent, permission of the study and ethical clearance was taken from the concerned department prior to the study.
Results
In this study, 100 hypothyroid patients (diagnosed by clinical and biochemical findings) were taken to observe the demographic profile as well as the prevalence of TPO-Abs among hypothyroid patients before L-thyroxine replacement therapy. Mean ages of the hypothyroid patients were 23.7 ± 4.9 years, which revealed that young adults were most commonly affected than elderly people and a female preponderance (74%) was also observed. Nearly 90% of the patients complained of tiredness followed by weight gain (83%), dry skin (71%), leg swelling (70%), hoarseness of voice (66%), constipation (57%) and cold intolerance (53%). Goitorous hypothyroid patients were (28%). Anaemia was present in majority of cases (81%); periorbital edema (54%) and cold periphery (30%) were noted. Among all cases 84% of the patients were TPO-Ab positive and rest 16% was TPO-Ab negative. Patients who had TSH value >10miu/L, 88.24% of them were TPO-Ab positive and those who had TSH value in between 6 to 10, 66.67% of them were TPO-Ab positive. Among 74 female hypothyroid patients, 62 (83.78%) were TPO-Ab positive, whereas out of 26 male hypothyroid patients, 22 (84.26%) were TPO-Ab positive.
Outcome of treatment of hypothyroidism with Lthyroxine in patients with high level of serum thyroid peroxidase antibodies (TPO Abs > 1000 IU/ml) and in those without high level of serum TPO Abs (≤ 1000 IU/ml) were assessed. The outcome was evaluated in terms of clinical and biochemical responses to treatment. Among a number of clinical signs and symptoms, 12 signs and symptoms (based on weighted manner) were considered of value to find a composite clinical score. A score of '1' was assigned for the presence and '0' for the absence of each of those symptoms and signs (described in Material & Methods) so that a total score ranging from 0 -12 could be attained by a patient depending upon the number symptoms and signs the patients had. To this score '1' point was added for female patients younger than 55 years old. The composite score thus obtained was divided into three categorieshypothyroid (score 6 or more), intermediate (score [3] [4] [5] and euthyroid (score 2 or less). The biochemical response was evaluated after a minimum treatment of 12 weeks (median treatment was 16 weeks) whether the levels of serum TSH and T 4 returned to normal range. The level of TSH was again subdivided into three categories-Overt hypothyroidism (TSH > 10 nmol/L), subclinical hypothyroid (TSH 6.01 -10 nmol/L) and normal or euthyroid (TSH 6 or less than 6 nmol/L). The clinical and biochemical responses was first assessed relative to composite clinical score and serum TSH and T 4 at baseline and then the outcome was compared between patients with high serum TPO Abs (> 1000 IU/ml) and patients without high serum TPO Abs (≤ 1000 IU/ml) to determine whether high serum TPO Abs played any role in modifying the clinical and biochemical responses to treatment. The findings of the study obtained from data analyses are chronologically presented below. Table I presents the association between high TPO Abs and clinical response. Of the 17 patients with high TPO Abs at baseline, only 17.6% turned into euthyroid (based on composite clinical score), whereas about 42% of the patients who did not have high TPO Abs became euthyroid suggesting that patients with high TPO Abs may show significantly poor response to treatment compared to the patients without high TPO Abs (p < 0.001). # Data were analyzed using Chi-square (χ 2 ) Test and were presented as frequency (%).
High TPO Abs and clinical response:

High TPO Abs and biochemical response:
Table IX demonstrates the association between high TPO Abs and biochemical response. Over threequarter (76.5%) of the patients with high TPO Abs exhibited serum TSH level 6 or below 6 nmol/L, 17.6% had overt and only 1 (5.9%) case had subclinical hypothyroidism. Majority (81.4%) of the patients with TPO Abs 1000 or less than 1000 nmol/L also had serum TSH 6 or below 6 nmol/L, 16.3% had overt and 1 (2.3%) case had subclinical hypothyroidism. Serum TPO Abs level was not observed as the determinant of biochemical response (p = 0.774). # Data were analyzed using Chi-square (χ 2 ) Test and were presented as frequency (%).
Discussion
Iodine deficiency remains the most common cause of hypothyroidism world-wide. In areas of iodine sufficiency, autoimmune diseases (both atrophic and goitorous form of Hashimoto's thyroiditis) and iatrogenic causes (treatment of hyperthyroidism) are the most common causes of hypothyroidism. Among 100 hypothyroid patients where 84% patients were TPO-Ab positive may indicate a higher proportion of patients are suffering from autoimmune thyroid disorder. Those who are in high titers (>1000 IU/mL) showed significantly poor response to treatment compared to the patients without high titers of TPO-Abs (p<0.001). So what precedes these events awaits further study. The present study had several limitations. The follow-up duration of study period was short. A significant proportion of patients lived in remote area and was very much reluctant to come at follow-up. Anti-TPO-Ab test was not available at Rajshahi and for that reason Investigator himself visited BSMMU, Dhaka with sample several times. It was time and cost consuming. TPO-Ab test was expensive. Following interferences may be drawn from the present study:
1. A significant proportion of hypothyroid patients in anti-TPO-Ab positive.
2. There is a decreased clinical and biochemical response to L-thyroxine replacement therapy among high titre TPO-Ab positive hypothyroid patients.
Conclusion
It is assumed that TPO-Ab plays a significant role in response to treatment with L-thyroxine replacement therapy. So, to get significant results of treatment with L-thyroxine to high titre TPOAb positive hypothyroid patients needs or awaits further study.
